Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

Completed

Conditions: Colorectal Cancer

Interventions: Drug: capecitabine
Drug: 5-fluorouracil
Procedure: Surgical Resection
Radiation: Radiation therapy

First Posted Date: 2006-01-23

Last Posted Date: 2022-08-11

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 47

Registration Number: NCT00280761

Locations: 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2006-01-20

Last Posted Date: 2012-02-14

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT00280176

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States

Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: AZD2171
Drug: 5-fluorouracil
Drug: Leucovorin
Drug: Bevacizumab
Drug: Oxaliplatin

First Posted Date: 2006-01-19

Last Posted Date: 2012-10-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 215

Registration Number: NCT00278889

Locations: 🇬🇧
Research Site, Sutton, United Kingdom
🇧🇪
Ressearch Site, Brussels, Belgium

Oxaliplatin and 5-FU Based Preoperative Chemoradiation

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: Oxaliplatin
Drug: Chemoradiation
Drug: 5-FU
Radiation: Preoperative chemoradiation
Procedure: Pelvic surgery
Drug: Neoadjuvant oxaliplatin

First Posted Date: 2006-01-18

Last Posted Date: 2016-09-29

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 109

Registration Number: NCT00278694

Locations: 🇳🇴
RRHF, Oslo, Norway

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Phase 2

Conditions: Colorectal Cancer

First Posted Date: 2006-01-11

Last Posted Date: 2010-02-01

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Target Recruit Count: 600

Registration Number: NCT00274872

Locations: 🇫🇷
Centre Hospitalier de Dreux, Dreux, France
🇫🇷
Hopital Louis Pasteur - Le Coudray, Le Coudray, France
🇫🇷
Institut Sainte Catherine, Avignon, France

and more 14 locations

Gemcitabine and Oxaliplatin Followed By Radiation Therapy, Fluorouracil, and Oxaliplatin in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 2

Conditions: Pancreatic Cancer

First Posted Date: 2006-01-11

Last Posted Date: 2009-02-09

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Registration Number: NCT00275119

Locations: 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷
CHU de Grenoble - Hopital de la Tronche, Grenoble, France
🇫🇷
Hopital Saint - Louis, La Rochelle, France

and more 8 locations

Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

Phase 3

Completed

Conditions: Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Stage II Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7

Interventions: Drug: Amifostine
Other: Laboratory Biomarker Analysis
Drug: Cisplatin
Radiation: Radiation Therapy
Drug: Fluorouracil

First Posted Date: 2006-01-11

Last Posted Date: 2022-10-25

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 111

Registration Number: NCT00274937

Locations: 🇺🇸
Driscoll Children's Hospital, Corpus Christi, Texas, United States
🇺🇸
Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 106 locations

Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2005-12-22

Last Posted Date: 2009-02-09

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Target Recruit Count: 39

Registration Number: NCT00268333

Locations: 🇫🇷
Polyclinique De Courlancy, Reims, France
🇫🇷
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz, Besancon, France
🇫🇷
Hopital Europeen Georges Pompidou, Paris, France

and more 6 locations

S0427, Combination Chemotherapy & RT in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx

Phase 3

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: cisplatin
Radiation: radiation therapy
Drug: docetaxel
Drug: 5-fluorouracil
Procedure: surgery

First Posted Date: 2005-12-22

Last Posted Date: 2012-10-04

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 6

Registration Number: NCT00268372

Locations: 🇺🇸
John H. Stroger, Jr. Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States

and more 69 locations

GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2005-12-07

Last Posted Date: 2013-10-16

Lead Sponsor: University of Rochester

Target Recruit Count: 50

Registration Number: NCT00262808

Locations: 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy